To assess the effect of NMDA receptors in the antidepressant-like effect of Yueju pill (YJ), we administered MK-801 (0.05mg/kg, i.p.)(9) 45 mins prior to the injection of YJ (1.35g/kg, i.g.), tail suspension test (TST), forced swimming test (FST) and open filed test (OFT) were performed after YJ treatment for 30 mins. Meanwhile, we also treat NMDA (75 mg/kg, i.p.) 30 mins prior to the injection of YJ (2.7g/kg, i.g.), TST, FST and OFT were performed after YJ treatment for 30 mins. Each behavior test used independent 32-40 mice. In another experiment, to investigate the role of NO in YJ -mediated antidepressant-like effect, we first administered L-Arginine (750 mg/kg, i.p.) 60 mins prior to the injection of YJ (2.7g/kg, i.g.), behavior tests were performed after YJ treatment for 30 mins. Then we injected L-NAME (10 mg/kg, i.p.) 45 mins prior to the treatment of YJ (1.35g/kg, i.g.), behavior tests were performed after YJ treatment for 30 mins. Furthermore, we treated (7-NI, 30 mg/kg, i.p.) 30 mins prior to the injection of YJ (1.35g/kg, i.g.), behavior tests were performed after YJ treatment for 30 mins. Finally, to evaluate the function of cGMP in antidepressant-like effect produced by YJ, methylene blue (10mg/kg, i.p.) was injected in mice 60 mins before the administration of YJ (1.35g/kg, i.g.), behavior tests were performed after YJ treatment for 30 mins. Also, sildenafil (5mg/kg, i.p.) was injected in mice 30 mins before the administration of YJ (1.35g/kg, i.g.), behavior tests were performed after YJ treatment for 30 mins. All the procedure was described in Figure S1 .
. The paradigm of the whole experiment about the drug treatments and behavior tests.
Injection of MK-801 alone or when combined with YJ did not affect the locomotor activity ( Fig.  S2a , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.348, P = 0.5589), pretreatment (F (1, 36) = 0.02288, P = 0.8806) and of treatment × pre-treatment interaction (F (1, 36) = 0.02022, P = 0.8877)) or central time (Fig. S2b , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 1.172, P = 0.2863), pre-treatment (F (1, 36) = 0.004268, P = 0.9483) and of treatment × pre-treatment interaction (F (1, 36) = 0.0005566, P = 0.9813)) during OFT. NMDA alone or when combined with effective doses of YJ (2.7g/kg), failed to elicit any effect on ambulatory activity of mice during OFT ( Fig. S2c , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.001282, P = 0.9580), pre-treatment (F (1, 36) = 0.02302, P = 0.8803) and of treatment × pre-treatment interaction (F (1, 36) = 0.1316, P = 0.7189); Fig. S2d , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.4899, P = 0.4885), pre-treatment (F (1, 36) = 0.8141, P = 0.3729) and of treatment × pre-treatment interaction (F (1, 36) = 0.1491, P = 0.7017)). Scores are expressed as the mean ± SEM, n=10 animals/group and were analyzed using two-way ANOVA followed by Bonferroni's post-test.
Injection of L-Arginine alone or when combined with YJ failed to affect the locomotor activity ( Fig.  S3a) during OFT. A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.6924, P = 0.4108), pre-treatment (F (1, 36) = 0.5367, P = 0.4685) and of treatment × pre-treatment interaction (F (1, 36) = 2.03, P = 0.1628). Meanwhile, L-Arginine alone or combined with YJ also didn't affect the anxiety behavior (central time) during OFT ( Fig. S3b) . A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.2202, P = 0.6417), pre-treatment (F (1, 36) = 1.849, P = 0.1823) and of treatment × pre-treatment interaction (F (1, 36) = 1.181, P = 0.2845). Fig. S3c and S3d clearly validated that co-injection of YJ (1.35g/kg) with L-NAME failed to bring any significant changes in locomotor behavior [ Fig. S3c , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 1.449, P = 0.2365), pre-treatment (F (1, 36) = 1.815, P = 0.1864) and of treatment × pre-treatment interaction (F (1, 36) = 0.007419, P = 0.9318)] or anxiety behavior [ Fig. S3d , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 1.978, P = 0.1681), pre-treatment (F (1, 36) = 1.581, P = 0.2168) and of treatment × pre-treatment interaction (F (1, 36) = 0.1624, P = 0.6893)] of animals during OFT. Fig. S3e and Fig. S3f revealed the effects of 7-NI administration alone or with YJ combination. No significant change was found in locomotor activity [A two-way ANOVA revealed the main effect of treatment (F (1, 28) = 0.0489, P = 0.8266), pre-treatment (F (1, 28) = 0.3187, P = 0.5769) and of treatment × pre-treatment interaction (F (1, 28) = 0.249, P = 0.6217)] or anxiety behavior [A twoway ANOVA revealed the main effect of treatment (F (1, 28) = 0.081, P = 0.7780), pre-treatment (F (1, 28) = 0.1596, P = 0.6925) and of treatment × pre-treatment interaction (F (1, 28) = 0.04017, P = 0.8426)] during OFT. Scores are expressed as the mean ± SEM, n=10 animals/group and were analyzed using two-way ANOVA followed by Bonferroni's post-test.
Administration of methylene blue (MB) alone or in combination with YJ did not show any significant effect (p > 0.05) on locomotor activity [Fig. S4a , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.4803, P = 0.4927), pre-treatment (F (1, 36) = 0.105, P = 0.7478) and of treatment × pre-treatment interaction (F (1, 36) = 0.004815, P = 0.8275)] or anxiety behavior [ Fig. S4b , A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 0.03025, P = 0.8629), pre-treatment (F (1, 36) = 0.01549, P = 0.9016) and of treatment × pre-treatment interaction (F (1, 36) = 0.007308, P = 0.9323)] during OFT. Sildenafil administration, alone or in combination with YJ did not show any significant effect on locomotor activity [Fig S4c, A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 1.805, P = 0.1875), pre-treatment (F (1, 36) = 1.551, P = 0.2211) and of treatment × pre-treatment interaction (F (1, 36) = 0.1085, P = 0.7437)] or central time [Fig S4d, A two-way ANOVA revealed the main effect of treatment (F (1, 36) = 3.265e-005, P = 0.9955), pre-treatment (F (1, 36) = 1.993, P = 0.1666) and of treatment × pre-treatment interaction (F (1, 36) = 1.46, P = 0.2349)] during OFT. 
